Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Thrombosis
Biotech
Hemab uses $135M series B to target neglected blood disorders
Pharma's focus on hemophilia has come at the expense of a range of intriguingly named but less well-known blood clotting disorders.
James Waldron
Feb 21, 2023 4:07am
Easing blood clotting through a new pathway
Jan 11, 2022 7:10am
Hemab raises $55M to target multiple rare bleeding indications
Jul 22, 2021 3:00am
Abbott racks up 2 new U.S., EU approvals for Xience stents
Jul 1, 2021 9:53am
New discoveries in eye regeneration and blood clots—News of Note
Aug 28, 2017 3:48pm
CeloNova’s nanocoated coronary stent wins FDA nod
Mar 1, 2017 11:13am
